Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P68133

UPID:
ACTS_HUMAN

ALTERNATIVE NAMES:
Alpha-actin-1

ALTERNATIVE UPACC:
P68133; P02568; P99020; Q5T8M9

BACKGROUND:
The protein Actin, alpha skeletal muscle, also known as Alpha-actin-1, is integral to various types of cell motility. Its expression in all eukaryotic cells highlights its essential role in maintaining cellular integrity and facilitating movement.

THERAPEUTIC SIGNIFICANCE:
Alpha-actin-1's involvement in diseases such as Congenital myopathy 2A, 2B, 2C, and Myopathy, scapulohumeroperoneal, underscores its clinical significance. These conditions, caused by variants in the gene encoding Alpha-actin-1, manifest in muscle weakness and developmental challenges. Targeting Alpha-actin-1 could thus be key in developing treatments for these muscle disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.